The Genetic Institute, Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel.
Neuromuscular Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel.
J Neurol Sci. 2019 Jul 15;402:62-68. doi: 10.1016/j.jns.2019.05.006. Epub 2019 May 8.
to determine the occurrence of homozygous rare, in-silico damaging variants in a genetically relatively homogenous group of amyotrophic lateral sclerosis (ALS) patients.
Whole-exome-sequencing of 43 ALS patients of North-Africa Jewish origin was performed. Data were filtered to identify very rare homozygous recessive in-silico damaging variants, in genes annotated to ALS-associated cellular pathways.
We identified a rare missense homozygous variant, p.Arg663Cys in MFN2, predicted to be damaging, in a patient with an early age at disease onset (36 years) and fast progression. An additional ALS patient carried the mutation and together established its association to ALS (p = .01). Additional homozygous variants were identified, including the risk allele p.Arg261His in NEK1, as well as variants in genes known to be associated with other neurodegenerative diseases, such as HTT (Huntington's disease), ATM (Ataxia-Telangiectasia), and ZFYVE26 (SPG15), and variants in genes previously reported as upregulated (LZTS3) or downregulated (ARMC4, CFAP54, and MTHFSD) in ALS patients. Altogether, 13 patients (30%) carried at least one homozygous rare in-silico damaging variant, of them 10 carried either another rare homozygous variant and/or a variant in a known ALS gene, which is categorized as pathogenic, likely-pathogenic or variant of uncertain significance.
Our results suggest the contribution of recessive alleles to ALS and the possibility of burden of mutations, emphasizing the complexity of ALS genetics.
确定在遗传上相对同质的肌萎缩侧索硬化症(ALS)患者群体中纯合罕见、计算机预测有害的变异的发生情况。
对 43 名北非裔犹太人来源的 ALS 患者进行全外显子组测序。对数据进行过滤,以鉴定在与 ALS 相关的细胞途径中注释的基因中非常罕见的纯合隐性遗传的计算机预测有害变异。
我们在一名发病年龄较早(36 岁)且病情进展迅速的患者中发现了 MFN2 中罕见的错义纯合隐性变异,p.Arg663Cys,预测该变异具有致病性。另一名 ALS 患者携带该突变,并共同确定其与 ALS 的相关性(p=0.01)。还鉴定到其他纯合变异,包括 NEK1 中的风险等位基因 p.Arg261His,以及与其他神经退行性疾病相关的基因(如亨廷顿病的 HTT、共济失调毛细血管扩张症的 ATM 和 SPG15 的 ZFYVE26)中的变异,以及先前报道在 ALS 患者中上调(LZTS3)或下调(ARMC4、CFAP54 和 MTHFSD)的基因中的变异。共有 13 名患者(30%)携带至少一种纯合罕见的计算机预测有害变异,其中 10 名患者携带另一种罕见的纯合变异和/或已知 ALS 基因中的变异,这些变异被归类为致病性、可能致病性或意义不明的变异。
我们的结果表明,隐性等位基因可能导致 ALS,并可能存在突变负担,强调了 ALS 遗传学的复杂性。